Oleoylethanolamide-based Treatment in Obesity: A Retrospective Analysis of 100 Cases from a Single Center in the Northern Territory of India

Background& Objectives: New therapeutic approaches with minimal or no adverse effects are needed to contain and counter the epidemic of obesity. Oleoylethanolamide is a bioactive lipid mediator shown to cause satiety, weight loss, and lipolysis in clinical studies. This retrospective analysis investigated the characteristics of patients initiated on the combination of oleoylethanolamide (200 mg), pantethine (75 mg) and valine (10 mg) treatment in routine clinical care and further assessed subsequent changes in weight, glycaemic and metabolic profile. Method: The analysis reviewed electronic records of 100 obese patients treated with the above combination between July 15, 2018 and December 15, 2018. Results: At the end of 3 months, daily intake of the above combination reduced the mean weight (6.16 kg), waist circumference (4.77 cm), total body fat (3.14 %) and BMI (1.99 kg/m2), significantly (p less than 0.01). The mean values of liver enzymes (ALT, and AST) and lipid parameters (TC, TG, LDL) also reduced significantly from baseline. The daily fullness increased in 76 % of patients and the cravings reduced in 85 % of patients. Conclusion: The above results suggest that the combination of OEA, pantethine, and valine could be effective in suppressing appetite and controlling weight in obese people.